



Nexstim Plc: Managers' Transactions, Karvinen

Company Announcement, Helsinki, 22 May 2023 at 12:10 PM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:

Person subject to the notification requirement

Name: Mikko Karvinen

Position: Chief Executive Officer

Issuer: Nexstim Oyj

LEI: 743700S7ZI0LNMHZ6Y27

Notification type: INITIAL NOTIFICATION

Reference number: 32095/5/6

Transaction date: 2023-05-17

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023A

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 46896 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 46896 Volume weighted average price: 0 EUR

Transaction date: 2023-05-17

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023B

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 46402 Unit price: 0 SEK

Aggregated transactions (1):

Volume: 46402 Volume weighted average price: 0 SEK

Transaction date: 2023-05-17

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023C

Nexstim

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 45909 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 45909 Volume weighted average price: 0 EUR

Further information is available on the website www.nexstim.com, or by contacting:

Leena Niemistö, Chair of Board of Directors

+358 9 2727 170

leena.niemisto@nexstim.com

The Company's Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com